Medincell Stock

Medincell EBIT

The EBIT of Medincell (MEDCL.PA) as of Aug 23, 2026 is -25.50 M EUR. In the previous year, EBIT was -13.19 M EUR — a change of 93.31% (lower).

EBIT

-25.50 MEUR

YoY

93.31%

Last updated:

In 2026, Medincell's EBIT was -25.50 M EUR, a 93.31% increase from the -13.19 M EUR EBIT recorded in the previous year.

The Medincell EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2024
-20.33 M EUR
Jan 1, 2025
-13.19 M EUR
Jan 1, 2026
-25.50 M EUR
Jan 1, 2027 (e)
-41.44 M EUR
Jan 1, 2028 (e)
-59.74 M EUR
Jan 1, 2029 (e)
-99.70 M EUR
Jan 1, 2030 (e)
-94.95 M EUR
Jan 1, 2031 (e)
-117.05 M EUR
The Medincell EBIT history
YEAREBITYoY
est-117.05 MEUR+23.27%
est-94.95 MEUR-4.76%
est-99.70 MEUR+66.88%
est-59.74 MEUR+44.16%
est-41.44 MEUR+62.53%
-25.50 MEUR+93.31%
-13.19 MEUR-35.13%
-20.33 MEUR-27.58%
-28.08 MEUR+22.28%
-22.96 MEUR+37.34%
-16.72 MEUR-13.74%
-19.38 MEUR+10.23%
-17.58 MEUR+132.58%
-7.56 MEUR+111.06%
-3.58 MEUR-950.83%
421,000.00EUR
Access this data via the Eulerpool API

Medincell Revenue

Medincell Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
9.16 M EUR
-20.33 M EUR
-25.04 M EUR
Jan 1, 2025
25.54 M EUR
-13.19 M EUR
-18.44 M EUR
Jan 1, 2026
19.52 M EUR
-25.50 M EUR
-31.29 M EUR
Jan 1, 2027 (e)
44.14 M EUR
-41.44 M EUR
1.48 M EUR
Jan 1, 2028 (e)
58.92 M EUR
-59.74 M EUR
12.45 M EUR
Jan 1, 2029 (e)
114.05 M EUR
-99.70 M EUR
49.82 M EUR
Jan 1, 2030 (e)
108.62 M EUR
-94.95 M EUR
51.37 M EUR
Jan 1, 2031 (e)
133.90 M EUR
-117.05 M EUR
78.83 M EUR

Medincell Margins

Medincell stock margins

The Medincell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medincell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medincell.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
100.00 %
-221.98 %
-273.34 %
Jan 1, 2025
100.00 %
-51.64 %
-72.19 %
Jan 1, 2026
100.00 %
-130.61 %
-160.27 %
Jan 1, 2027 (e)
100.00 %
-93.88 %
3.36 %
Jan 1, 2028 (e)
100.00 %
-101.39 %
21.12 %
Jan 1, 2029 (e)
100.00 %
-87.42 %
43.68 %
Jan 1, 2030 (e)
100.00 %
-87.42 %
47.29 %
Jan 1, 2031 (e)
100.00 %
-87.42 %
58.87 %

Medincell Stock analysis

What does Medincell do? Medincell SA is a leading biotechnology company based in Montpellier, France, specializing in the development and manufacturing of innovative drugs based on its proprietary Intellisome® technology platform. The company was founded in 1999 by Dr. Christophe Douat and has since built an impressive portfolio of products and services. Medincell's business model is based on the development and manufacturing of extended-release drugs through the integration of drugs into the Intellisome® technology platform. This is a novel concept based on the use of polymers that are capable of controlling and slowing down the release of drugs. This allows medications to be administered in a specific dosage and duration, providing greater effectiveness and tolerability for the patient. Medincell has several business areas, including the development of drugs for the treatment of central nervous system (CNS) disorders, including schizophrenia, depression, and chronic pain. The company is also working on the development of drugs for the treatment of infectious diseases and cancer, as well as the development of new technologies for drug manufacturing. Medincell's products include a range of drugs, including Long-Acting Risperidone (a depot preparation for the treatment of schizophrenia), Long-Acting Cabergoline (for the treatment of Parkinson's), and Long-Acting Naltrexone (for the treatment of alcohol and drug addiction). The company also has partnerships with other pharmaceutical companies such as Pierre Fabre, Sanofi, Janssen, and Pfizer for the development of products based on its Intellisome® technology platform. Another important area of Medincell is its service for drug development based on the Intellisome® technology platform. The company offers customers comprehensive support in the development, manufacturing, and approval of extended-release drugs. Customers can choose from a wide range of services, ranging from the identification of active ingredients to the implementation of clinical trials. Overall, Medincell has achieved impressive success in the launch of its products and services based on the Intellisome® technology platform. The company has won several awards for its innovative products and services in the pharmaceutical industry, including the Innovation Award from the European Society of Clinical Microbiology and Infectious Diseases in 2018 and the Excellence in Specialty Pharmaceuticals Award from BioPharm America in 2019. In summary, Medincell SA is a leading company in the biotechnology industry specializing in the development and manufacturing of extended-release drugs based on its Intellisome® technology platform. With an impressive range of products and services and partnerships with several renowned pharmaceutical companies, the company has a promising future as a key player in the pharmaceutical industry. Medincell is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Medincell's EBIT

Medincell's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Medincell's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Medincell's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Medincell’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Medincell stock

EBIT of Medincell is -25.50 M EUR in 2026.

EBIT of Medincell changed from -13.19 M EUR to -25.50 M EUR, representing a 93.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Medincell since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Medincell historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Medincell

All Key Metrics — Medincell